LON:BVX BiVictriX Therapeutics (BVX) Share Price, News & Analysis Add Compare Share Share Stock Analysis Stock Analysis About BiVictriX Therapeutics Stock (LON:BVX) Get BiVictriX Therapeutics alerts:Sign Up Key Stats Today's Range N/A50-Day Range N/A52-Week Range N/AVolume1.54 million shsAverage Volume108,326 shsMarket Capitalization£8.25 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview BiVictriX Therapeutics Plc, a biotechnology company, engages in the development of cancer therapies in the United Kingdom. The company develops Bi-Cygni therapeutics, which are selective for cancer types. Its lead program is BVX001, focuses on acute myeloid leukaemia, as well as develops BVX002 and BVX003 for various blood cancers and solid tumours. BiVictriX Therapeutics Plc was founded in 2016 and is headquartered in Macclesfield, the United Kingdom. Read More Receive BVX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BiVictriX Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. BVX Stock News HeadlinesBiVictrix Therapeutics Share Chat (BVX:JPJ)April 15, 2025 | lse.co.ukBivictrix quits London’s AIM to chase private funding as market ‘undervalues’ firmAugust 12, 2024 | msn.comMy $247 scanner for $7Bill Poulos is cutting the price of his $247 Instant Scanner to $7 for Black Friday. It's a one-time payment that covers a full year, with no subscription and no re-bills. Every night after the close, the scanner screens nearly a thousand of America's biggest stocks. It returns a short list of qualifying setups with the exact buy price next to each one. There's nothing to install. If you decide it's not for you, you get the $7 back and keep the scanner for the year. | Profits Run (Ad)BiVictriX Therapeutics Proposes Delisting From London's AIMAugust 12, 2024 | marketwatch.comWhen Will BiVictriX Therapeutics Plc (LON:BVX) Turn A Profit?February 15, 2024 | finance.yahoo.comBiVictriX Therapeutics' former chair moves onDecember 6, 2023 | proactiveinvestors.comBRIEF-Bivictrix Therapeutics PLC Extended Survival Rates Reported With Bvx001 In A Pre-Clinical Model Of Acute Myeloid LeukaemiaOctober 12, 2023 | reuters.comBiVictriX says latest preclincial leukaemia data could accelerate progressOctober 12, 2023 | proactiveinvestors.comSee More Headlines Industry, Sector and Symbol Stock ExchangeLON SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolLON:BVX CIKN/A Webwww.bivictrix.com PhoneN/AFaxN/AEmployees17Year FoundedN/AProfitability EPS (Trailing Twelve Months)GBX (0.04) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-£2.67 million Net MarginsN/A Pretax MarginN/A Return on Equity-103.99% Return on Assets-62.99% Debt Debt-to-Equity Ratio8.81 Current Ratio4.40 Quick Ratio7.49 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash Flow2.20 Book ValueGBX 3 per share Price / BookN/AMiscellaneous Outstanding Shares82,530,000Free FloatN/AMarket Cap£8.25 million OptionableNot Optionable Beta-0.73 The Infrastructure's Backbone: 10 Stocks Powering the AI BuildoutThe AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.Get This Free Report This page (LON:BVX) was last updated on 9/10/2024 by MarketBeat.com Staff. From Our PartnersYour $7 scanner is waitingThe Instant Scanner is $7 in Bill Poulos's Black Friday sale. Every night it delivers a list showing which sto...Profits Run | SponsoredPentagon magnet restrictions take effect January 1, 2027A NASDAQ-listed company has signed a term sheet outlining a potential 75-year agreement with the U.S. Army. It...OilPrice | SponsoredTop Trader Reveals Stunning Black Friday DealOthers paid $500 for the Snapback Indicator. This Black Friday, it's available for just $7. Base Camp Tradi...Base Camp Trading | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredMy public warning after 55 years of watching the marketsDr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredYour secret “Black Friday” link for tradersMarkham Trading's complete Alpha Oracle Signal system is just $7 for Black Friday. Others paid nearly $2,000 f...TradeWins | Sponsored432 miles southeast of Washington, DC…Spruce Pine, North Carolina, a town of just over 2,000 people, has supplied a material to every major chip mak...Wall Street Watchdogs | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BiVictriX Therapeutics Plc Please log in to your account or sign up in order to add this asset to your watchlist. Share BiVictriX Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.